Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
AI Inc, Apr-Dec (Cumulative 3Q) Net Income Turns to Loss, Oct-Dec Net Income Turns to Loss
4388 AI,Inc. 【J-GAAP】
Earnings ReportAI,Inc. <4388> [TSE Growth] announced its financial results after the market closed on February 5th (15:30). The consolidated net income/loss for the cumulative third quarter of the fiscal year ending March 2025 (April to December) turned into a loss of 86 million yen (compared to a profit of 53 million yen in the previous period non-consolidated).
Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income for the January to March period (4Q) is expected to drop 32.1% from the previous period non-consolidated to 38 million yen.
In the most recent three-month period, from October to December (3Q), the consolidated net income/loss turned to a loss of 86 million yen (compared to a profit of 62 million yen in the previous period non-consolidated). The operating profit margin sharply declined from 21.4% in the same period last year to 4.7%.
Note: Since the current fiscal year, the company has transitioned to consolidated financial statements.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Apr - Dec, 2022 | 459 | -6 | -6 | -4 | -1.0 | ー | Jan 31, 2023 | J-GAAP |
Apr - Dec, 2023 | 514 | 50 | 51 | 53 | 10.8 | 63.0 | Feb 5, 2024 | J-GAAP |
Apr - Dec, 2024 | 885 | 32 | 57 | -86 | -15.6 | 54.8 | Feb 5, 2025 | J-GAAP |
YoY | +72.2% | -36.0% | +11.8% | - | - |
Current Period Guidance
Second Half Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Mar, 2023 | 435 | 77 | 77 | 118 | 24.0 | 0 | May 14, 2024 | J-GAAP |
Oct - Mar, 2024 Guidance | 1,075 | 106 | 96 | -48 | -7.2 | - | Nov 7, 2024 | J-GAAP |
YoY | +147.1% | +37.7% | +24.7% | - | - |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Mar, 2023 | 633 | 19 | 22 | 16 | 3.3 | 0 | May 11, 2023 | J-GAAP |
Mar, 2024 | 734 | 81 | 81 | 109 | 22.2 | 0 | May 14, 2024 | J-GAAP |
Mar, 2025 Guidance | 1,475 | 115 | 104 | -48 | -7.2 | - | Nov 7, 2024 | J-GAAP |
YoY | +101.0% | +42.0% | +28.4% | - | - |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Dec, 2023 | 215 | 46 | 47 | 62 | 12.6 | 21.4 | Feb 5, 2024 | J-GAAP |
Jan - Mar, 2024 | 220 | 31 | 30 | 56 | 11.4 | 14.1 | May 14, 2024 | J-GAAP |
Apr - Jun, 2024 | 217 | 3 | 3 | 4 | 1.0 | 1.4 | Aug 6, 2024 | J-GAAP |
Jul - Sep, 2024 | 183 | 6 | 5 | -4 | -1.1 | 3.3 | Nov 7, 2024 | J-GAAP |
Oct - Dec, 2024 | 485 | 23 | 49 | -86 | -15.6 | 4.7 | Feb 5, 2025 | J-GAAP |
YoY | +125.6% | -50.0% | +4.3% | - | - |
Related Articles
KYORIN Pharma, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 30%, Oct-Dec Ordinary Profit Decreases by 55%
FUJI KYUKO, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 7%
Noevir, Oct-Dec (1Q) Ordinary Profit Decreases by 8%
NIHON KOHDEN, Oct-Dec (3Q) Ordinary Profit Increases by 16 times
TOBU RAILWAY, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 2%
ORGANO, The Current Fiscal Year Ordinary Profit Revised Upward by 9%, Raises Record High Profit Forecast
NISHIO HOLDINGS, Oct-Dec (1Q) Ordinary Profit Increases by 16%
SHOFU, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 22%, Oct-Dec Ordinary Profit Increases by 14%
SBI RHEOS HIFUMI, 11% Increase in Undisclosed Ordinary Profit, Record High for The First Time in Three Years
WAKAMOTO PHARMA, Apr-Dec (Cumulative 3Q) Ordinary Profit Loss Widens, Oct-Dec Ordinary Profit Turns to Loss